Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

23 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis.
Parolia A, Eyunni S, Verma BK, Young E, Liu L, George J, Aras S, Das CK, Mannan R, Rasool RU, Luo J, Carson SE, Mitchell-Velasquez E, Liu Y, Xiao L, Gajjala PR, Jaber M, Wang X, He T, Qiao Y, Pang M, Zhang Y, Alhusayan M, Cao X, Tavana O, Hou C, Wang Z, Ding K, Chinnaiyan AM, Asangani IA. Parolia A, et al. Among authors: rasool ru. bioRxiv [Preprint]. 2024 Mar 29:2024.02.22.581560. doi: 10.1101/2024.02.22.581560. bioRxiv. 2024. PMID: 38464251 Free PMC article. Preprint.
Cellular reprogramming in vivo initiated by SOX4 pioneer factor activity.
Katsuda T, Sussman JH, Ito K, Katznelson A, Yuan S, Takenaka N, Li J, Merrell AJ, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. Among authors: rasool ru. Nat Commun. 2024 Feb 26;15(1):1761. doi: 10.1038/s41467-024-45939-z. Nat Commun. 2024. PMID: 38409161 Free PMC article.
Loss of LCMT1 and biased protein phosphatase 2A heterotrimerization drive prostate cancer progression and therapy resistance.
Rasool RU, O'Connor CM, Das CK, Alhusayan M, Verma BK, Islam S, Frohner IE, Deng Q, Mitchell-Velasquez E, Sangodkar J, Ahmed A, Linauer S, Mudrak I, Rainey J, Zawacki KP, Suhan TK, Callahan CG, Rebernick R, Natesan R, Siddiqui J, Sauter G, Thomas D, Wang S, Taylor DJ, Simon R, Cieslik M, Chinnaiyan AM, Busino L, Ogris E, Narla G, Asangani IA. Rasool RU, et al. Nat Commun. 2023 Aug 29;14(1):5253. doi: 10.1038/s41467-023-40760-6. Nat Commun. 2023. PMID: 37644036 Free PMC article.
Physiological reprogramming in vivo mediated by Sox4 pioneer factor activity.
Katsuda T, Sussman J, Ito K, Katznelson A, Yuan S, Li J, Merrell AJ, Takenaka N, Cure H, Li Q, Rasool RU, Asangani IA, Zaret KS, Stanger BZ. Katsuda T, et al. Among authors: rasool ru. bioRxiv [Preprint]. 2023 Feb 14:2023.02.14.528556. doi: 10.1101/2023.02.14.528556. bioRxiv. 2023. PMID: 36824858 Free PMC article. Updated. Preprint.
Oncofusion-driven de novo enhancer assembly promotes malignancy in Ewing sarcoma via aberrant expression of the stereociliary protein LOXHD1.
Deng Q, Natesan R, Cidre-Aranaz F, Arif S, Liu Y, Rasool RU, Wang P, Mitchell-Velasquez E, Das CK, Vinca E, Cramer Z, Grohar PJ, Chou M, Kumar-Sinha C, Weber K, Eisinger-Mathason TSK, Grillet N, Grünewald TGP, Asangani IA. Deng Q, et al. Among authors: rasool ru. Cell Rep. 2022 Jun 14;39(11):110971. doi: 10.1016/j.celrep.2022.110971. Cell Rep. 2022. PMID: 35705030 Free PMC article.
Toppling the HAT to Treat Lethal Prostate Cancer.
Rasool RU, Natesan R, Asangani IA. Rasool RU, et al. Cancer Discov. 2021 May;11(5):1011-1013. doi: 10.1158/2159-8290.CD-21-0184. Cancer Discov. 2021. PMID: 33947717
23 results